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ABSTRACT: Many scientiﬁc studies present removal eﬃcien-
cies for pharmaceuticals in laboratory-, pilot-, and full-scale waste-
water treatment plants, based on observations that may be
impacted by theoretical and methodological approaches used.
In this Critical Review, we evaluated factors inﬂuencing observed
removal eﬃciencies of three antibiotics (sulfamethoxazole,
ciproﬂoxacin, tetracycline) in pilot- and full-scale biological
treatment systems. Factors assessed include (i) retransformation
to parent pharmaceuticals from e.g., conjugated metabolites and
analogues, (ii) solid retention time (SRT), (iii) fractions sorbed
onto solids, and (iv) dynamics in inﬂuent and eﬄuent loading.
A recently developed methodology was used, relying on the
comparison of removal eﬃciency predictions (obtained with the
Activated Sludge Model for Xenobiotics (ASM-X)) with representative measured data from literature. By applying this
methodology, we demonstrated that (a) the elimination of sulfamethoxazole may be signiﬁcantly underestimated when not
considering retransformation from conjugated metabolites, depending on the type (urban or hospital) and size of upstream
catchments; (b) operation at extended SRT may enhance antibiotic removal, as shown for sulfamethoxazole; (c) not accounting
for fractions sorbed in inﬂuent and eﬄuent solids may cause slight underestimation of ciproﬂoxacin removal eﬃciency. Using
tetracycline as example substance, we ultimately evaluated implications of eﬄuent dynamics and retransformation on environ-
mental exposure and risk prediction.
■ INTRODUCTION
Biological wastewater treatment plants (WWTPs) have a crucial
role in the mitigation of the risk posed by the release of pharma-
ceuticals in receiving environmental bodies. The elimination of
pharmaceuticals in conventional WWTPs is presently consid-
ered insuﬃcient, and a number of substances of concern for
the aquatic environment have been identiﬁed at national1,2 and
regional levels.3 Among existing pharmaceutical classes, research
has focused on antibiotics because of their ubiquitous usage,
their overall recalcitrance to biological wastewater treatment,
and more recently, antibiotic resistance spread by WWTP emis-
sions.4−7
Because of the comparably high costs and the uncertainty
inherent in the analysis of pharmaceuticals, simulation models
represent an appealing option to investigate their fate and
elimination in biological WWTPs. Two recent review articles8,9
summarized the approaches used for fate prediction of
xenobiotic trace chemicals in wastewater, including pharma-
ceuticals. Nevertheless, adequate assessment of pharmaceutical
elimination in biological WWTPs still remains a challenge,
considering the high variability of measured removal eﬃciencies
presented in literature for the same substance.6,10−13 Thus,
combining modeling and experimental/analytical eﬀorts oﬀers
the opportunity for a thorough understanding of elimination
mechanisms in WWTPs. It also represents a valuable option
for decision support to operators and legislators, given the
progressive implementation of WWTP upgrade measures to
reduce emissions of trace chemicals.14−17
In the last three decades, ever since pharmaceuticals were
detected in aqueous media, several review articles on the fate of
pharmaceuticals and, more speciﬁcally, antibiotics during
wastewater treatment have been published.5,6,10,12,18−31 The
main objective of this study was to complement previous
assessments by critically evaluating factors inﬂuencing the
elimination of antibiotics and by testing a model-based method-
ology to identify the inﬂuence of such factors. The assessment
focused on the inﬂuence of (i) retransformation to parent
antibiotics via, for example, metabolite deconjugation, (ii) solid
retention time (SRT) in secondary treatment, (iii) fractions
sorbed onto inﬂuent and eﬄuent solids, and (iv) intrinsic
dynamics in inﬂuent and eﬄuent loading. The developed
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methodology relies on the generalization of the calibrated Acti-
vated Sludge Modeling Framework for Xenobiotics (ASM-X32−34)
with full-scale international removal eﬃciency data thoroughly
selected from peer reviewed literature. The methodology,
already tested for diclofenac and carbamazepine,33 was further
considered for three antibiotics (sulfamethoxazole, SMX;
ciproﬂoxacin, CIP; tetracycline, TCY), for which the model
had already been calibrated and evaluated with batch and full-
scale experimental data, respectively.32 An overview of the
therapeutic use of the selected antibiotics is provided in the
Supporting Information.
■ FACTORS AND PROCESSES INFLUENCING
ANTIBIOTIC REMOVAL IN WWTPS
Retransformation Processes. In the following subsec-
tions, we assess in detail a number of processes responsible for
“negative” removal eﬃciencies35 observed in full-scale WWTPs
for parent pharmaceuticals. A critical overview of processes,
not traditionally accounted for when assessing pharmaceutical
fate, is provided to propose a more integrated approach to fate
assessment.
Deconjugation of Metabolites. The human metabolism of
administered pharmaceuticals involves two types of mecha-
nisms, that is, functionalization reactions (e.g., oxidation, hydro-
xylation, reduction, mostly catalyzed by CYP450 enzymes) and
conjugation reactions (e.g., glucuronidation, sulfation, acetyla-
tion). The latter mechanisms increase the polarity of organic
molecules to facilitate their excretion. The traditional distinc-
tion of these reactions as Phase I and Phase II metabolism,
respectively, has been lately questioned, as direct conjugation of
parent pharmaceuticals frequently occurs.36,37 Conjugated
metabolites of parent pharmaceuticals can undergo retrans-
formation back to the parent form following cleavage of the
conjugated moiety. Importantly, this type of conjugates can
represent up to one-quarter (22%) of ﬁrst-step pharmaceutical
metabolites,37 indicating a potential for the formation of parent
forms after excretion.
Microbial deconjugation of human metabolites to parent
forms has been hypothesized or observed in wastewater for
estrogens,38−40 carbamazepine,33,41−44 and its functionalized
metabolites44−46 and diclofenac.33,47,48 For the latter two
substances, deconjugation was considered to explain concen-
tration increases from WWTP inﬂuent to eﬄuent. Although the
signiﬁcance of deconjugation during wastewater treatment has
been acknowledged, detailed empirical evidence is still scarce,
being limited to estrogens, because of analytical challenges.49−52
With respect to the antibiotics considered in this study,
the metabolism has been widely investigated, allowing for the
identiﬁcation of potentially retransformable excreted forms.
A detailed description of the metabolism and excretion of
SMX, CIP and TCY and their metabolites is presented in the
Supporting Information (Figures S1−S4 and Table S1). The
human metabolism of SMX involves the excretion of acetylated
(N4-acetyl-SMX) and glucuronide (SMX-N1-Glu, SMX-2′-Glu)
conjugates of the parent substance, which combined in urine
account from 50% up to 75% of an administered dose of SMX
(Figure S4 and Table S1).53,54 Extensive literature exists on the
deconjugation of the major metabolite, N4-acetyl-SMX, during
wastewater treatment.55−59 Retransformation of acetylated
metabolites back to parent forms has also been observed
for other sulfonamides in aqueous media.60 More recently,
SMX-N1-Glu was detected in preclariﬁed
61 and ﬁnal WWTP
eﬄuent62 and receiving surface water bodies,63 possibly
indicating its persistence (as for other N-glucuronide
pharmaceutical metabolites44). Conversely, almost complete
elimination (>90%) was observed during secondary treatment61
and comparably fast microbial deconjugation of SMX-N1-Glu
occurred in water-sediment tests.64 Excreted conjugated
metabolites of CIP include sulfo-CIP and N-formyl-CIP, the
former being the main conjugated metabolite (up to 17% of an
administered dose).65,66 Minor excretion of the glucuronide
conjugate (CIP-Glu) has also been reported,67 although this
metabolite has never been identiﬁed in wastewater. To the
authors’ knowledge, microbial deconjugation of sulfo-CIP in
aqueous media has not been investigated, but can be postulated
in analogy with other sulfate metabolites (e.g., of natural and
synthetic estrogens40,68,69). Orally and intravenously adminis-
tered TCY undergoes limited metabolism in humans, being
excreted mainly in unchanged form (Figure S1).70−72 No
formation of conjugated metabolites has been reported.
Abiotic Retransformation of Metabolites and Trans-
formation Products. Minor excretion (5%) of TCY in the
form of the optical isomer 4-epi-tetracycline (4-epi-TCY) has
been reported.73,74 4-epi-TCY has been also identiﬁed as abiotic
transformation product of TCY in aqueous solution,75 activated
sludge,76 and manure.77−79 In liquid media, epimerization of
TCY was shown to be reversible, mostly occurring under acidic
and neutral conditions.77,80 Epimerization is catalyzed by the
presence of anions,80 whereas reverse epimerization is facili-
tated in the presence of divalent cations at pH > 6.81,82 Up to
70% abiotic retransformation of 4-epimers of TCY and its
analogues was shown in soil and activated sludge at pH = 8.1
and in the presence of magnesium and calcium ions.76 Reversible
epimerization, with formation of TCY from 4-epi-TCY, is thus
identiﬁable as abiotic retransformation process. 4-epi-TCY concen-
tration was quantiﬁed in two hospital eﬄuents at μg L−1 levels,83
being 11% and 35% of corresponding TCY concentration. Com-
parable concentrations of TCY and 4-epi-TCY (∼100 ng L−1)
were also measured in the inﬂuent of a municipal WWTP, where
almost complete removal of the two substances was reported to
occur via sorption onto activated sludge.84
Nitration and nitrosation are common abiotic transformation
mechanisms for trace chemicals containing aromatic groups.85
The formation of nitrated products was shown in pure and
mixed nitrifying cultures for the estrogen 17α-ethinyl estradiol
(EE2)86−89 and acetaminophen,90 being associated with
signiﬁcant accumulation of nitrite or peroxynitrite and acidic
pH conditions. Nitrated and nitrosated derivatives were further
identiﬁed and quantiﬁed (at low ng L−1 levels) in full-scale
WWTPs for SMX91 and diclofenac.91−93 Although nitration
and nitrosation appear of limited importance during conven-
tional treatment of domestic wastewater,85−89 these mecha-
nisms may be relevant to the treatment of high strength reject
water and/or in deammoniﬁcation and nitrite shunt processes,
where nitrite accumulation is more likely to occur. Notably,
parent SMX was shown to be abiotically formed from its
nitrosated (via photolysis)63 and nitrated94 derivatives.
Formation from Analogues and Structurally Related
Chemicals. Pharmaceuticals and their human metabolites can
be additionally formed from other commercial chemicals (a) as
a result of human metabolism and (b) as products of bio-
logical transformation processes during, for example, waste-
water treatment. Formation typically occurs from substances
exhibiting structural similarity to the formed pharmaceutical.
Examples are oxazepam, a benzodiazepine pharmaceutical and a
human metabolite of the analogues diazepam and temazepam,
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and atenolol acid, a human metabolite of metoprolol and a
transformation product of atenolol.95−97 Formation from other
commercial chemicals via metabolism (following veterinary
use) and environmental biodegradation have been reported for
CIP and TCY. CIP was observed to be a metabolite (up to 47%
of the administered dose98−100), fungal degradation product,101
and photolysis product102 of enroﬂoxacin. Rolitetracycline,
a tetracycline analogue used for veterinary therapy, can be
metabolized to TCY.103
Release from Faecal Matter. Concentration increases
between the inﬂuent and the eﬄuent of a primary clariﬁer
were reported for ﬂuoroquinolones, including CIP,104,105
and macrolides,56 possibly resulting from the release from
faeces to the aqueous phase.56 Similar observations were made
for macrolides by comparing full-scale WWTP inﬂuents and
eﬄuents.106−108 Although signiﬁcant macrolide amounts have
been detected in raw inﬂuent solids,59 alternative hypotheses
were made to explain macrolide formation.109 Release from
faecal matter is relevant to CIP and TCY, considering the
substantial excretion of these antibiotics in faeces (9%−52%,
Table S1).66,72
Hydrolysis of Particulate and Colloidal Matter. Particulate
matter in biological wastewater treatment includes microbial
cells, bacterial decay products, exocellular polymeric substances,
hydrolyzable and colloidal organic matter and inorganic
material.110−115 Hydrolyzable and colloidal organics undergo
hydrolysis by extracellular enzymes,116,117 with potential release
of sorbed trace chemicals to the aqueous phase. Sorption onto
colloidal matter in activated sludge was found signiﬁcant for
hydrophobic chemicals (e.g., polycyclic aromatic hydro-
carbons).111−113 As for pharmaceuticals, little information is
available on the sorption onto diﬀerent matrices. In activated
sludge, partitioning of 17α-ethinylestradiol to dissolved and
colloidal matter was found to be negligible compared to sludge
particles.118 Nevertheless, partitioning of CIP and TCY to
organic constituents other than particulates can be expected
relevant, as previously shown for municipal biosolids119 or
puriﬁed humic acids.120
Desorption. CIP and TCY are multivalent zwitterions with
strong dipole, having high water solubility and comparably
low logD. Nevertheless, both chemicals exhibit signiﬁcant
sorption capacity onto suspended solids and sludge.121−124
Sorption of these chemicals mainly occurs via hydrophobicity-
independent mechanisms (e.g., electrostatic attraction, cation
bridging).119,125−131 Sorption equilibria for CIP are strongly
inﬂuenced by pH and ionic strength, and can change under
varying conditions in biological wastewater treatment.124
A similar behavior can be postulated for TCY, based on pre-
vious observations of pH-dependent sorption in soils.128
Further observations33,122,132,133 showed that signiﬁcant
fractions of sorbed pharmaceuticals can be sequestered in the
sludge matrix, undergoing slow or no desorption (sorption
hysteresis132) and thus not being in equilibrium with the
aqueous phase.
Solid Retention Time (SRT). The inﬂuence of the solid
retention time (SRT) on the elimination of pharmaceuticals has
been the object of intense investigation in the past decade.
Macroscopically, SRT-related eﬀects were observed in terms of
increased pharmaceutical transformation: (i) in the presence of
nitriﬁers (supported at SRT greater than 5 d in fully aerobic
systems and 8−10 d in aerobic-anoxic systems134), as compared
to heterotrophs only;89,135−149 and (ii) in systems with extended
physical retention of microbial biomass and thus operating at
prolonged SRTs (e.g., membrane bioreactorsMBRs, bioﬁlm
reactors).10,26,33,39,57,58,150−162 In both cases, the inﬂuence of
SRT could be explained by changes induced in microbial
communities, and two hypotheses have been considered to
summarize such beneﬁts.
On the one hand, SRT has a positive eﬀect on the microbial
diversity by inducing an expansion of the microbial community.
This has been demonstrated in laboratory-163 and full-scale155
activated sludge systems. Increased biodiversity may stem from
the enrichment of slow-growing bacteria21 (e.g., nitriﬁers),
specialist degrader strains155,164,165 responsible for speciﬁc
transformation processes166 and K-strategists, capable of
eﬃciently utilizing resources at low concentrations.153,155 This
may translate into an enhancement of the overall biotransfor-
mation potential of the community. On the other hand, at
prolonged SRT biomass is increasingly exposed to limiting
substrate availability conditions, resulting from operation at
reduced food-to-microorganism (F/M) ratios. Under oligo-
trophic conditions, the microbial metabolism of heterotrophic
bacteria relies on fortuitous oxidation (resulting from low
enzyme speciﬁcity)167,168 or the utilization of multiple sub-
strates at low concentration (mixed substrate growth).169,170
Through broad expression of enzymes responsible of cata-
bolism, bacteria can utilize organic substances not typically used
as growth substrates169−172 (a strategy also referred to as meta-
bolic expansion).21
In mixed culture systems, extended SRT results in the enrich-
ment of slow-growing nitriﬁers and the concomitant exposure
of heterotrophs to growth substrate limiting conditions, both
likely favorable toward trace chemical biotransformation. For
the estrogen EE2, heterotrophic bacteria have been found to
biodegrade transformation products generated by ammonia
oxidizers, thereby demonstrating an example of cooperative
contribution toward the removal of trace chemicals.89
To date, evidence of the inﬂuence of SRT on biotransformation
capacity has been disputed or could not be generalized for all pharma-
ceuticals investigated,39,42,57,58,87,89,136,139,143,145−148,150,156,158,160,173−178
leading to the conclusion that the impact of SRT may be
chemical-speciﬁc. In a number of cases, controversial results
have been obtained for the same substance (e.g., trimetho-
prim,89,137 atenolol145,173), possibly indicating the interference
of experimental and methodological approaches used. Among
other sources of variability, growth substrate availability
(abundance or limitation), growth conditions (batch or chemo-
stat), and the resulting physiological state of biomass may have
inﬂuenced observations of trimethoprim biotransformation by
nitriﬁers.86,89 In the Supporting Information, we provided a
detailed overview of relevant literature investigating the impact
of SRT on the elimination of pharmaceuticals and other trace
chemicals.
■ FACTORS INFLUENCING THE QUANTIFICATION
OR THE PREDICTION OF ANTIBIOTIC REMOVAL IN
WWTPS
Inﬂuent-Eﬄuent Dynamics and Sampling. The release
of down-the-drain chemicals (e.g., pharmaceuticals) into sewer
systems and to WWTPs is inherently dynamic. Antibiotics are
excreted and discharged in sewer pipelines as a result of discrete
toilet ﬂushes, resulting in short-term loading variations.179−181
Attenuation of ﬂuctuations is shown for substances exhibiting
high sorption aﬃnity onto solids in sewers.182 At wider
temporal scale, patterns in loading dynamics to WWTPs have
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been recognized for several pharmaceuticals and associated with
(i) seasonal variations in pharmaceutical consumption and
(ii) diurnal variations as a function of their administration
patterns and half-life in human body.42,183−186 Inﬂuent
generator algorithms have been developed (using stochastic
or deterministic approaches) to predict pharmaceutical loading
in WWTP inﬂuents.187
Conventionally, the elimination of pharmaceuticals in full-
scale WWTPs is calculated or predicted based on inﬂuent and
eﬄuent concentrations or loads. Capturing loading dynamics in
WWTP inﬂuents and eﬄuents is therefore crucial for an
unbiased estimation of removal eﬃciencies, and is adequately
achieved only by adopting the proper sampling strategy. Load
variations, and consequently the selection of the sampling
protocol, are inﬂuenced by several factors, namely, (i) the type
of chemical, its usage and its pathway of discharge in the sewer
network (determining the frequency and the shape of pulses
through which the chemical is released in the sewer); (ii) the
size and shape of the catchment (determining to what extent
ﬂuctuations are buﬀered as a result of in-sewer dispersion);
(iii) the type of drainage system employed in the sewer
network (determining variations of ﬂow rates in WWTP
inﬂuents).180,188−191 According to the guidelines proposed by
Ort et al.,188 truly averaged concentrations of pharmaceuticals
in inﬂuents and eﬄuents of WWTPs serving middle-sized or
large catchments can be measured by collecting daily ﬂow-
proportional composite samples. Additionally, the sampling
error can be minimized by appropriately selecting the sampling
frequency based on the expected number of pulses. The impact
of WWTP residence time distribution on chemical concen-
trations in eﬄuents may further require pooling of raw inﬂuent
samples collected in consecutive days.192 Sampling require-
ments to determine long-term (e.g., annual) inﬂuent loads of
antibiotics have been further estimated.186 Importantly, when
assessing removal in speciﬁc sections of WWTPs, i.e. only
during biological treatment, treatment steps located upstream
(e.g., primary clariﬁcation) may contribute to reducing load
ﬂuctuations as compared to raw inﬂuent.183
For smaller catchments (e.g., hospitals), where the variation
of concentrations is expected to be signiﬁcantly higher due to
reduced dispersion (shorter in-sewer residence time) or lower
number of pulses expected (limited number of consumers),193
high-frequency (<5 min) or continuous ﬂow-proportional
sampling may be required.96,194
Collection and analysis of composite and continuous
wastewater samples involves the storage of wastewater in
automatic samplers and (typically after ﬁltration) in laboratories
under refrigerated conditions (from −20° to 4 °C). The
stability of trace chemicals, and more speciﬁcally antibiotics,
during wastewater storage has been investigated else-
where.195−197 However, no conclusive evidence exists on the
stability of SMX, CIP, and TCY and their human metabolites.
Rather high instability of glucuronide conjugates (i.e.,
morphine-glucuronide) was shown in raw and ﬁltered waste-
water at 2 °C, and could be prevented by acidiﬁcation.195
Nevertheless, the use of acidiﬁcation during wastewater
collection (e.g., by means of preventive acid addition to
sampling ﬂasks) has been questioned due to the interference
with pH-dependent sorption equilibria of ionizable chemicals,
leading to changes in aqueous and sorbed concentrations.195
Signiﬁcant release of sorbed amounts to the aqueous phase due
to pH decrease may for instance be expected for CIP.124
Laboratory-Scale Estimation of Process Parameters.
Sampling campaigns in full-scale WWTPs are often comple-
mented, if not replaced, with laboratory-scale experiments
under controlled conditions. Targeted batch or continuous-ﬂow
experiments are used to derive fate parameters (namely,
biotransformation rate constants, kBio, and solid−liquid
partition coeﬃcient, Kd), based on which full-scale elimination
can be estimated. The reliability of estimated parameters is
ensured only if experiments are carried out under environ-
mentally representative conditions. We hereby identiﬁed and
discussed a number of factors and associated pitfalls, some of
which have been addressed elsewhere,198 inﬂuencing observa-
tions made on pharmaceutical fate in laboratory-scale waste-
water systems.
Underestimation of kBio by Measuring Parent Pharma-
ceutical Concentrations in Continuous-Flow and Batch
Experiments. By monitoring concentrations of only parent
pharmaceuticals in laboratory-scale experiments, retransforma-
tion processes leading to the formation of parent pharmaceut-
icals and thus masking their true elimination are in practice
ignored. This may occur in continuous-ﬂow experiments, when
monitoring inﬂuent and eﬄuent of biological reactors, or in
batch experiments, when spiking only parent pharmaceuticals at
concentrations similar to indigenous levels of retransformable
chemicals.
Over- or Underestimation of Representative kBio in Batch
Tests at Concentration Levels Signiﬁcantly Higher than in
the Environment. Pharmaceuticals, typically prevailing at
trace levels in sewage and other environmental media, can be
deﬁned as nongrowth substrates. Although early studies199,200
showed that laboratory-scale tests at concentrations greater
than those in nature may not be representative of conditions
typical of natural ecosystems, spiking of reference substances is
still common practice.201 Signiﬁcant variations in measured
removal eﬃciencies or estimated kBio, depending on the initial
concentration level, were recently shown for several pharma-
ceuticals in wastewater, for example, ibuprofen,175,202,203
diclofenac,203 and clarithromycin.175 A recent detailed study
on trimethoprim204 demonstrated that diﬀerent spiking levels
signiﬁcantly inﬂuenced not only kinetics, but also pathways of
biotransformation. Speciﬁcally, high concentrations of anti-
biotics may result in the inhibition of bacteria and/or enzymes
responsible of their biotransformation, thus impacting trans-
formation kinetics and pathways (as hypothesized for
trimethoprim).204 No signiﬁcant variation of biotransformation
kinetics (by biomass enriched in synthetic growth medium) was
conversely shown at two diﬀerent spiking levels of salicylic acid
and trimethoprim under extant conditions.142
Over- or Underestimation of kBio from Experiments Run in
the Excess of Growth Substrates. Typically present in waste-
water in ng L−1 to μg L−1 concentration levels, pharmaceuticals
are considered nongrowth substrates, not providing energy
beneﬁt to cells. Biological transformation is regarded as a come-
tabolic process, whereby primary substrates (COD, nutrients)
support biomass growth and energy supply.145,167,200,205−207
Under conditions of limiting growth substrate availability (e.g.,
at extended SRT), biotransformation may stem from mixed
substrate utilization strategies169−171 or fortuitous metabo-
lism.167,168 Furthermore, growth substrates can competitively
inhibit or enhance the biotransformation of trace chemicals,207
including pharmaceuticals.32,33,198 Spiking of reference pharma-
ceuticals in batch or continuous-ﬂow experiments involves the
addition of carbon (e.g., in the form of methanol), in which
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spiked substances are dissolved. Biomass is thus provided with
excess organic carbon in readily biodegradable form, thereby
inﬂuencing observations of biological transformation by
heterotrophic biomass198 or ultimately causing a shift in micro-
bial communities even in short-term batch experiments.208
Underestimation of kBio by Using Synthetic Growth
Medium in Long-Term Experimental Studies. Biotransforma-
tion experiments are often conducted with biomass enriched by
long-term feeding with synthetic wastewater. Such media often
contain a limited range of growth substrates, as compared to
real wastewater, thereby inﬂuencing the adaptation potential
of biomass and minimizing the possible induction of gene
expression, responsible for an eﬀective heterotrophic bio-
transformation, by indigenous chemicals structurally similar to
trace analytes.201,205,209,210 For instance, enhanced estrogen
biotransformation rates were found in the presence of
recalcitrant organic substrate (mainly bacterial decay and lysis
products), typically absent in synthetic media, as compared to
reference readily biodegradable substrate.210
Overestimation of Sorption Coeﬃcients (Kd) by Using
Pharmaceutical Concentration in Solids, Possibly Propagat-
ing to kBio Estimates. Pharmaceutical concentrations present in
solid phase (e.g., activated sludge) may include a sequestered
fraction, not in equilibrium with aqueous concentrations and
thus not potentially bioavailable following desorption. Desorp-
tion experiments132,133 and modeling exercises33 accordingly
showed the signiﬁcance of irreversibly sequestered fractions of
pharmaceuticals in sewage sludge.
The inﬂuence of the factors described above on assessing
pharmaceutical biotransformation is exempliﬁed in Figure 1,
where estimated kBio under aerobic and anoxic conditions for a
range of pharmaceuticals are presented and compared. We
distinguished between kBio values obtained (Figure 1a) in mixed
culture experiments with activated sludge and real wastewater,
without pharmaceutical spiking32−34 and (Figure 1b) in
enriched activated sludge fed with synthetic wastewater and
spiking of reference substances.143,211 In the latter case, more
pronounced deviation between aerobic and anoxic kBio is
noticed. Major discrepancies can be noticed, for example, for
diclofenac (DCF).
■ MATERIALS AND METHODS
Description and Full-Scale Implementation of ASM-X.
In the ASM-X version developed for antibiotics,32 three states
are used to describe the concentrations (ng L−1) of diﬀerent
fractions: (i) the dissolved parent fraction (CLI), (ii) the sorbed
parent fraction (CSL), and (iii) the retransformable fraction
(CCJ). The variable CCJ identiﬁes chemicals undergoing retrans-
formation to CLI via the processes described above. Fate
processes include the biotransformation of CLI, retransforma-
tion of CCJ back to CLI and sorption (desorption) onto (from)
sludge. The parameters used in process rate equations include
the biotransformation rate constant, kBio (L gTSS
−1 d−1), the
retransformation rate constant, kDec (L gTSS
−1 d−1), the solid−
liquid partition coeﬃcient, Kd (L gTSS
−1), and the desorption
rate, kDes (d
−1). A detailed description of the ASM-X structure,
including state variables and parameters, is provided in the
Supporting Information (Table S2).
A parameter is deﬁned to characterize the parent-
to-retransformable ratio in inﬂuent sewage, that is (eq 1),
=n C C/LI,CJ LI,in CJ,in (1)
where CLI,in and CCJ,in denote the inﬂuent concentration of
parent and retransformable fractions, respectively.
Figure 1. Comparative assessment of transformation rate constants estimated under aerobic and anoxic denitrifying conditions by (a) Plośz
et al.32−34 and (b) Suaŕez et al.143 (triangles) and Su et al.211 (circles). Reported values refer to rate constants for biotransformation (biot, kBio),
cometabolic biotransformation in the presence of growth substrate (biot-c, qBio)
33 and retransformation (retr, kDec). Substances assessed include:
sulfamethoxazole (SMX), tetracycline (TCY), ciproﬂoxacin (CIP), cocaine (COC), benzoyl-ecgonine (BE), ecgonine-methyl-ester (EME),
diclofenac (DCF), carbamazepine (CBZ), galaxolide (HHCB), natural estrogens E1 and E2, tonalide (AHTN), celestolide (ADBI), ibuprofen (IBP),
17α-ethinyl estradiol (EE2), ﬂuoxetine (FLX), roxithromycin (ROX), erythromycin (ERY), citalopram (CIT), naproxen (NPX), diazepam (DZP),
salicylic acid (SAL), trimethoprim (TMP), and nonylphenol (NPH).
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The full-scale ASM-X implementation in WEST 2012 (DHI,
Denmark), with parameters (kBio, kDec, Kd, nLI,CJ) estimated
from batch experimental results and evaluated with measure-
ments performed in a 3-day sampling campaign in Bekkelaget
WWTP (Oslo, Norway), was used to estimate the elimination
of the selected antibiotics. Further details on biological treat-
ment in Bekkelaget WWTP are presented in the Supporting
Information and elsewhere.32,33,183 For a meaningful comparison
with literature data, scenario simulations were performed using
increased or decreased inﬂuent loads of pharmaceuticals, as
compared to full-scale measurements.32
Generalization: Concepts. Removal Eﬃciency Calcula-
tion. The full-scale removal eﬃciency of SMX, CIP, and TCY
was calculated based on preclariﬁed and secondary eﬄuent
concentrations of these substances. We distinguished between
removal eﬃciency [−] based only on the dissolved parent
fraction (parent-based removal eﬃciency ηLI, eq 2)
η = −M M M( )/LI LI,in LI,eff LI,in (2)
and on both parent and retransformable fractions (total removal
eﬃciency ηTOT, eq 3)
η = + − −
+
M M M M
M M
( )
/( )
TOT LI,in CJ,in LI,eff CJ,eff
LI,in CJ,in (3)
where M denotes chemical mass load (μg h−1 or μg d−1), the
subscripts “LI” and “CJ” identify parent and retransformable
fractions, respectively, and the subscripts “in” and “eﬀ” identify
secondary inﬂuent and eﬄuent, respectively. Estimated ηLI and
ηTOT were plotted as a function of the normalized inﬂuent load
of pharmaceuticals (mg h−1 1000 PE−1), which was calculated
from the inﬂuent ﬂow rate (Qin) and design capacity in terms of
PE of the WWTP. We note that the design PE does not
correspond to the population served by each WWTP, and is
used to allow for a comparison between measured data from
diﬀerently sized WWTPs and predicted removal eﬃciencies.
Review of Published Removal Data. A literature review was
performed to collect removal eﬃciency data for SMX, CIP and
TCY. International data on pilot- and full-scale removal of
pharmaceuticals were included in this study only if the corre-
sponding literature source responded to a number of criteria:
(i) the wastewater sampling protocol used was explicitly reported
and data presented were obtained by applying sound sampling
techniques (see Inﬂuent−Eﬄuent Dynamics and Sampling
section), based on information provided in the publication;
(ii) removal eﬃciencies during secondary treatment could
be calculated, where not explicitly reported, from published
data (e.g., concentrations in secondary inﬂuent and eﬄuent);
(iii) additional information on the WWTP assessed was suﬃ-
ciently detailed, including average inﬂuent ﬂow rate of the
WWTP or inﬂuent ﬂow rate in the sampling period, HRT, SRT,
and the design capacity in terms of PE. To our knowledge, a
number of literature studies46,55,56,104,105,121,159 complied with
these criteria. These studies investigated pharmaceutical elimi-
nation in conventional activated sludge (CAS), ﬁxed bed bio-
ﬁlm reactors (FBR) and membrane bioreactors (MBR). In addi-
tion, measurements by Yang et al.212 in secondary WWTP
inﬂuent were used to discuss variability of the parameter nLI,CJ
(eq 1) in full-scale WWTPs. Further details on full-scale WWTPs
and catchments investigated in the mentioned literature studies
are presented in the Supporting Information (Tables S5−S6).
Zero-Catchment Scenario. Literature studies on in situ
treatment of hospital eﬄuent were selected to characterize a
“zero-catchment” scenario, describing the removal of pharma-
ceuticals in WWTPs with negligible upstream sewer transport.
Literature data96,213,214 were used to assess antibiotic removal
in WWTPs treating hospital wastewater (MBR, hybrid bioﬁlm-
activated sludge, HYBAS and moving bed bioﬁlm reactor,
MBBR respectively) and compared with ASM-X predictions.
In this way, we aimed at addressing the potential impact of
retransformation processes, not occurring in upstream sewer
but only via biological treatment, on the observed elimination.
As hospital WWTP capacity is usually expressed in terms of
hospital beds, predictions and measured data were compared
assuming that 1 bed was equivalent to 3.4 PE96 based on the
wastewater production per bed in the study and the wastewater
production per PE (200 L d−1 PE−1).215
Presentation of Results. ASM-X generalization was
performed by plotting estimated ηLI and ηTOT against the
normalized inﬂuent load of pharmaceuticals. An optimal way to
present these results was found in operating plots that were
constructed using 6-h average inﬂuent loads and removal
eﬃciency (Figure S5).33 In this way, we accounted for two
crucial factors, inﬂuencing the calculation of removal
eﬃciencies: (i) dynamics in the inﬂuent loads of pharmaceut-
icals, observed during the sampling period; and (ii) residence
time and consequent dispersion eﬀect in the simulated
WWTP.192 Removal eﬃciency predictions were presented
under a range of loading conditions, and could be used for
comparison with literature removal data, usually referred to
24-h up to 3-d composite samples. In Figure S5, predicted
removal eﬃciency curves are deﬁned using the mean of predic-
tions (dashed black line) and an uncertainty interval (light or
dark gray) based on standard deviation of 6-h removal eﬃciency
predictions. Examples of the interpretation of operating plots are
directly provided in the Results and Discussion section and
further details are given in the Supporting Information.
Dynamic Risk Assessment. A preliminary assessment of
the environmental risk, associated with the release of residual
pharmaceuticals to surface water, was performed. Based on
ASM-X predictions,32 predicted environmental concentrations
(PECs) were estimated from Bekkelaget secondary eﬄuent
concentration (eqs 4 and 5)
= CPEC /DFLI LI,eff (4)
= +C CPEC ( )/DFTOT LI,eff CJ,eff (5)
where CLI,eff and CCJ,eff (ng L
−1) denote the measured secondary
eﬄuent concentrations of parent and retransformable fraction,
respectively.
We distinguished between PECs accounting for only eﬄuent
CLI (PECLI) and for both eﬄuent CLI and CCJ (PECTOT).
A default dilution factor (DF) of 10 was assumed for the
estimation.216 Quasi-MECs (concentrations in freshwater esti-
mated from measurements in WWTP eﬄuent1) were also
estimated from measured CLI in secondary eﬄuent.
32 PECs and
quasi-MECs were ﬁnally compared to predicted no-eﬀect con-
centrations (PNECs) reported in literature, describing thresh-
old concentrations for risk in receiving water bodies. Risk was
associated with a pharmaceutical in Bekkelaget eﬄuent when
the ratio between PEC (or quasi-MECs) and PNEC (also
known as risk quotient, RQ) was greater than 1. Additionally,
the dynamics in eﬄuent concentrations (and therefore, in PECs
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and quasi-MECs) allowed for the assessment of trends and
extents of the risk during the sampling period.
■ RESULTS AND DISCUSSION
Sulfamethoxazole (SMX). Removal in Full-Scale WWTPs.
The elimination of parent SMX has been previously
investigated in conventional and advanced biological full-scale
WWTPs. Biotransformation has been recognized as the main
elimination mechanism of SMX,32,55,56,123,159 with minor
contribution from sorption onto sludge. Among all conjugated
metabolites of SMX, detailed evidence on the full-scale removal
of only N4-acetyl-SMX is available.
55,56 Sorption of N4-acetyl-
SMX was found to be negligible because of its high solubility
and polar nature (typical of conjugated metabolites).
Considering the absence of measurements on other conjugated
metabolites of SMX, namely SMX-N1-Glu, the retransformable
fraction CCJ of SMX in literature studies was assumed to be
entirely represented by N4-acetyl-SMX. We accordingly com-
pared predicted ηTOT with the combined removal eﬃciency of
SMX and N4-acetyl-SMX (also referred to as ηTOT in Figure 2).
Figure 2. Operating plots showing parent-based (ηLI) and total removal eﬃciencies (ηTOT) for SMX predicted by ASM-X and measured in full- and
pilot-scale WWTPs. Removal eﬃciencies are plotted as a function of the inﬂuent load of the antibiotic normalized by the WWTP capacity. The com-
parison between measured and predicted removal eﬃciencies is presented according to the following subdivision: (a) literature studies presenting only
parent-based removal eﬃciency; (b−c) literature studies presenting parent-based and total removal eﬃciencies in systems at SRT (b) lower than 16 d
and (c) higher than 16 d; (d) literature studies assessing hospital WWTPs in the “zero-catchment scenario”. SRT values for WWTPs considered in this
ﬁgure are reported in Table S5. Measured removal eﬃciencies denoted as ηTOT include the elimination of parent SMX and the conjugated metabolite
N4-acetyl-SMX. Scenario simulations to derive predicted ηLI and ηTOT in panels a, b−c, and d were run considering a 1.25-, 5-, and 25-fold increased
inﬂuent load, respectively. Scenario simulations to derive predicted ηLI and ηTOT at extended SRT in panel c were run assuming kBio = 3 L gTSS
−1 d−1.
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In Figure 2, ASM-X removal eﬃciency predictions (shaded
curves) are compared with measured removal eﬃciency (data
points) for SMX (and N4-acetyl-SMX, where possible). Pre-
dicted removal eﬃciency (ηLI and ηTOT) curves were obtained
simulating a 1.25-fold (Figure 2a) and 5-fold (Figure 2b−c)
increased inﬂuent loading of SMX as compared to Bekkelaget
WWTP. For a meaningful comparison, we distinguished
between literature studies assessing the elimination of parent
SMX only (Figure 2a) and literature studies assessing the
elimination of both SMX and N4-acetyl-SMX in WWTPs
operating at SRT lower than and 16 d (Figure 2b) and higher
than 16 d (Figure 2c). A threshold of 16 d represents the SRT,
at which Bekkelaget WWTP was operated during the sampling
campaign used for ASM-X evaluation.32,33
Overall, a large variability in measured removal eﬃciency for
SMX (from −150% to 80%) is evident from published data. To
explain the observed variability, studies assessing only the elimi-
nation of parent SMX46,159 are ﬁrst considered (Figure 2a).
Measurements are well approximated by ηTOT predictions, indi-
cating limited impact of retransformation during secondary
treatment as a result of low inﬂuent CCJ concentrations.
This hypothesis is supported by (a) the signiﬁcant formation
(+45%) of SMX during primary settling;46 (b) the input load
contribution from pharmaceutical manufacturing to the WWTP
investigated;159 (c) reduced concentrations of conjugates of
other sulfonamides (acetyl-sulfamethazine) in the primary
eﬄuent in the same WWTP;217 (d) the size of the WWTPs
investigated (Table S5), serving medium-to-large-sized catch-
ments with likely retransformation in upstream sewers. The sig-
niﬁcance of (d) is discussed later in the manuscript.
ASM-X predictions of ηLI and ηTOT are in close agreement
with removal eﬃciencies for SMX and SMX + N4-acetyl-SMX,
respectively, reported for Kloten−Opﬁkon WWTP55,56(CAS 1,
Switzerland; SRT < 16 d; Figure 2b). Low or negative ηLI (from
−107% to 9%) occurred as a result of the almost complete
retransformation, through deconjugation, of N4-acetyl-SMX
back to parent SMX. The underestimation error between ηLI
and ηTOT in Kloten-Opﬁkon (from −160% to 44%) was in the
error range predicted by ASM-X (from −200% to 60%). The
good agreement between measured (including N4-acetyl-SMX
as the only conjugate) and predicted ηTOT indicates that
the retransformable fraction in WWTPs may be almost
completely represented by the acetylated conjugate. Accord-
ingly, estimated kDec values
32 well approximate biotransforma-
tion rate constants for N4-acetyl-SMX in activated sludge
(Table S4). The other conjugated metabolite SMX-N1-Glu
may undergo (i) extensive and fast retransformation in upstream
sewers, with negligible presence in WWTP inﬂuent or (ii) limited
retransformation (and elimination) during biological waste-
water treatment.
Figure 2c presents ηLI and ηTOT predictions and measure-
ments in WWTPs operating at SRT higher than or equal to
16 d (16−80 d). Although SRT is not determined for attached
growth systems, removal eﬃciency data measured in FBR56
were also considered. Signiﬁcant variability is shown for mea-
sured ηLI (from −138% to 60%) due to observations in CAS2
WWTP. Minimum ηLI for CAS 2 (−138%) and FBR (−61%)
occurred when comparably higher loads of N4-acetyl-SMX
(nLI,CJ = 0.15) occurred in secondary inﬂuent. Again, the
reported data highlight the signiﬁcant underestimation error
arising by characterizing SMX removal only based on parent
SMX concentration. Importantly, measured ηLI and ηTOT
included in Figure 2c showed an overall increase when
compared to what presented in Figure 2b. Measured ηTOT
(60%−76%) in CAS 2 and FBR were generally higher than in
CAS 1 (from −1% to 53%). In addition, measured ηLI (37%−
40%) and ηTOT (70%−90%) in MBR (SRT = 16−80 d)
56 were
consistently higher than for CAS1 (Figure 2b) under similar
loading conditions (the two systems were operated in parallel).
As a consequence, most of the measured ηLI and ηTOT were
higher than respective prediction curves, indicating that retrans-
formation per se may not explain the variability in observed
removal eﬃciencies. We hypothesized that a kinetic improve-
ment of SMX biotransformation occurred in WWTPs operated
at SRT ≥ 16 d. A scenario simulation with ASM-X was per-
formed assuming increased biotransformation rate constant
for parent SMX (kBio = 3 L gTSS
−1 d−1; Figure 2c, “High SRT”
curves) to estimate and reproduce enhanced ηLI and ηTOT.
The obtained predictions were selected to describe the highest
measured removal eﬃciencies (MBR with SRT < 20 d).56
The estimated kBio is a comparably high value and the simulated
increase possibly lumps other eﬀects. We note that the
increased biomass concentration at which MBRs are typically
operated (2−3-fold higher TSS than in conventional WWTPs)
cannot alone explain the observed enhancement in SMX elimi-
nation. Accordingly, no further increase of ηLI or ηTOT as a func-
tion of SRT was observed (at SRT > 16 d) in the MBR.56
Overall, the model-based assessment of SMX elimination in
WWTPs suggests that the variability of observed removal
eﬃciency can be associated with the inﬂuence of conjugated
metabolites (namely, N4-acetyl-SMX) in secondary inﬂuents
and of the SRT set for WWTP operation. Such conclusions
were drawn only when removal of SMX and N4-acetyl-SMX
were simultaneously assessed, and could be used to explain
observations in other WWTPs.46,159
Zero-Catchment Scenario. Figure 2d presents ηLI and ηTOT
curves predicted with ASM-X (25-fold increased inﬂuent loading
of SMX compared to Bekkelaget WWTP), and published
removal eﬃciency measurements.96,213,214 In these studies, a
pilot MBR (SRT = 30−50 d, TSS = 2 g L−1) and two bioﬁlm
systems (HYBAS and MBBR), respectively, were operated for
decentralized treatment of hospital eﬄuent. In one study96
aqueous concentrations of both SMX and N4-acetyl-SMX
were measured, allowing for the calculation of ηLI and ηTOT.
The deviation between ηLI and ηTOT was also in this case
signiﬁcant (from 22% to 72%), in the error range predicted by
ASM-X. Both ηLI (from −53% to 26%) and ηTOT (from 6% to
48%) were lower than in the previously assessed MBR but
comparable to eﬃciencies achieved in CAS and FBR systems.
Measured ηLI data from the three studies were generally
underpredicted by ηLI curve, whereas measured ηTOT data
points were located on or below the corresponding ηTOT curve.
Considering the signiﬁcant elimination of N4-acetyl-SMX
(81% ± 4%), the absence of catchment between the hospital
eﬄuent and the pilot MBR could only to some extent explain the
observations. Inﬂuent nLI,CJ to the MBR (≥1 gLI gCJ−1) was on
average higher than in urban catchments32,55,56 and excreted
ratios expected from human pharmacokinetics (Figure S1).
Comparably lower concentrations of N4-acetyl-SMX in secon-
dary inﬂuent may therefore explain the generally higher ηLI
measurements as compared to ASM-X predictions. No evidence
of deconjugation in the primary clariﬁer, located upstream to the
MBR, was reported,96 indicating that speciﬁc nLI,CJ ratios were
intrinsic to the hospital eﬄuent (excluding that retransformation
occurred during sample storage and handling). We provided
a possible interpretation of observations by comparing nLI,CJ
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data from municipal and hospital WWTPs (see Impact of
Retransformation/In-Sewer Retransformation section, Figure 3).
As shown by the comparison between measured and predicted
ηTOT, the extended SRT in MBR, HYBAS, and MBBR could
not explain the enhancement of parent SMX elimination.
Impact of Retransformation/In-Sewer Retransformation.
By comparing measured removal eﬃciencies to ηLI and ηTOT
prediction curves (Figure 2), it was possible to quantify the
impact of retransformation from SMX conjugates back to
parent SMX in pilot- and full-scale biological WWTPs.
Variability in measured SMX removal eﬃciencies was explained
by diﬀerent parent-to-retransformable ratios (nLI,CJ) in secondary
inﬂuent due to transformation processes in sewer networks
upstream of WWTPs. To date, in-sewer biological trans-
formation processes (or “reactive sewer” concept) have been
systematically evaluated only for limited chemical groups,
for example, estrogens and their excreted conjugates.40,69,218
On the contrary, in-sewer processes have been considered not
relevant for antibiotics,186 whereas recent evidence219 showed
signiﬁcant formation of SMX (+66%) during transport in
pressurized sewer pipelines.
The extent of in-sewer retransformation of SMX conjugates
likely depends on: (i) the mean hydraulic retention time of raw
sewage in sewer pipelines; and (ii) redox conditions prevailing
in sewer systems. Very little evidence is available as to point
(ii) because only anaerobic conditions have been assessed219
and no information on transformation kinetics in raw sewage is
available. Mean residence times in upstream sewers are also not
typically reported in full-scale fate studies, making an evaluation
of their impact challenging.
Therefore, we evaluated the variability of nLI,CJ for SMX in
worldwide full-scale WWTP inﬂuents as a function of the
WWTP design capacity (in PE) (Figure 3). It was again
assumed that the retransformable fraction of SMX (CCJ) would
coincide with N4-acetyl-SMX concentration. The design
capacity is used here as an approximation of the catchment
size and is considered as a surrogate indicator of the mean
residence time in sewer systems. Our evaluation did not aim at
establishing mathematical correlations, and is based on a
number of assumptions/simpliﬁcations: (a) redox conditions
do not inﬂuence kinetics of SMX retransformation, as
preliminarily conﬁrmed by kDec values from various literature
sources (Table S4); (b) SMX consumption and excretion is
homogeneously distributed within a catchment; (c) diﬀerences
in residence time in gravity and pressurized sewers are not
considered; (d) diﬀerences in population density within studied
catchments are insigniﬁcant. A preliminary assessment showed
that the design capacity can give an indication of in-sewer mean
residence time (Table S7). Measured nLI,CJ in both raw and
preclariﬁed sewage were included (Figure 3), considering
evidence of deconjugation in primary settlers.46,55,56 Measured
nLI,CJ were compared with the range of expected ratios at the
excretion point.53,220
We ﬁrst considered nLI,CJ in the inﬂuent of full-scale
municipal WWTPs (design capacity > 10 000 PE). Measure-
ments by Göbel et al.55,56 approximated theoretical excreted
ratios, indicating limited retransformation in a small-sized
catchment (Table S7). A similar ratio was estimated for a larger
catchment (WWTP capacity = 281 000 PE) using a model-
based assessment.32 Signiﬁcantly higher nLI,CJ (>2 gLI gCJ
−1) was
measured in the secondary inﬂuent of large WWTP212
(capacity = 1 000 000 PE), indicating that extensive retrans-
formation may have occurred upstream to the sampling point.
These preliminary ﬁndings suggest that inﬂuent composition in
terms of parent and retransformable fractions, and thus the
extent of retransformation upstream to secondary treatment,
may depend on the catchment size. This could further explain
the observation of higher ηLI measurements (comparable to
predicted ηTOT) in WWTPs with 277 000 PE
159 and 740 000
PE46 (Figure 2a).
Measured nLI,CJ in raw and preclariﬁed hospital eﬄuent
96
were generally found higher than theoretical ratios at the
excretion point, thus explaining the underestimation of ηLI
measurements96,213,214 by ASM-X predictions (Figure 2d).
This evidence was not expected based on our hypothesis that
negligible in-sewer transport would correspond to limited
retransformation upstream to secondary treatment. We ex-
plored alternative interpretations, focusing on SMX con-
sumption and excretion in hospitals and households.
The fraction of SMX consumed or excreted in hospitals,
compared to the overall consumption/excretion in a speciﬁc
catchment, exhibits signiﬁcant geographical (Norway, < 1%;221
Australia and Italy, < 10%;194,222,223 Germany, 12%−18%;224
Switzerland, 16%−52%;225 Denmark, ∼100%, medstat.dk for
year 2013) and temporal variations.225 Even when admin-
istration occurs in hospitals, not negligible fractions of
pharmaceuticals may still be excreted in households because
of speciﬁc treatments or reduced hospitalization periods.194,226
Figure 3. Inﬂuent parent-to-retransformable ratios (nLI,CJ) for SMX in
pilot- and full-scale WWTPs as a function of catchment size. The catch-
ment size is here used to assess the extent of retransformation of
conjugated SMX back to parent SMX in sewers upstream of full-scale
WWTPs and its inﬂuence on raw and secondary inﬂuent composition
in terms of parent and conjugated SMX (expressed by nLI,CJ). Design
capacity in population equivalents (PE) of studied WWTPs is here
considered as an indicator of catchment size.
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Thus, only a limited fraction of pharmaceuticals administered in
hospital eﬀectively reaches hospital eﬄuents. Pharmacokinetic
studies have indicated slower elimination of N4-acetyl-SMX
(i.e., longer half-life) from human body than of parent SMX in
healthy54,227 and renally impaired subjects.228 Accordingly,
relative excreted amounts of SMX and N4-acetyl-SMX in urine
vary from the initial hours (e.g., in hospitals) to 48−96 h
(e.g., in households) after administration and, more impor-
tantly, higher nLI,CJ can be expected in hospital sewage. Notably,
theoretical nLI,CJ at the excretion point, derived from data in
Table S1, represent average values over 60−96 h after SMX
administration.
Overall, our observations point at the following conclusions:
(i) the impact of SMX formation during wastewater treatment
is more pronounced in small urban catchments/WWTPs,
where limited retransformation in upstream catchments is
expected, and (ii) temporal trends for the excretion of SMX
and its conjugated metabolites may have a signiﬁcant impact on
loads entering WWTPs that treat hospital sewage.
Impact of SRT and MBR Operation. By comparing
predicted and measured56 ηLI and ηTOT, it was possible to
identify enhanced removal eﬃciencies in municipal CAS, FBR,
and particularly, MBR WWTPs (SRT = 16−80 d). For the
MBR system, a comparison with removal eﬃciencies in a CAS
WWTP operated in parallel conﬁrmed that variability in
observations was not due to diﬀerent nLI,CJ ratios in inﬂuent.
Considering the almost complete removal of N4-acetyl-SMX
(>80%) in all WWTPs investigated, a kinetic improvement
of SMX biotransformation at SRT > 16 d likely caused the
enhanced SMX elimination. Through scenario simulations, we
suggested that improved biotransformation kinetics resulted
from a step increase of kBio, in agreement with previous ﬁndings
for diclofenac.33
In previous studies at SRT > 100 d,175,176 estimated kBio
values for SMX for laboratory- and pilot-scale MBRs were
found comparable to CAS (see Table S4 for comparison). This
may though be considered as limited evidence of the inﬂuence
of extended SRT on biotransformation kinetics of SMX.
Improved SMX elimination may be alternatively attributed to
higher TSS concentrations, at which MBRs are typically
operated.161 Notably, kBio values estimated to date (Table S4)
were normalized by the total biomass content (as TSS or VSS),
not accounting for the reduction of the active biomass fraction
at increasing SRT.57 Thus, it should not be excluded that the
biotransformation capacity of active biomass may be enhanced
at prolonged SRT (as a result of increased biodiversity or
improved metabolic capabilities)a hypothesis that could be
demonstrated only by assessing kBio normalized by active
biomass.
Overall, currently available evidence is still limited to provide
a valuable explanation of observed SMX elimination and thus to
support the hypothesis proposed in this study.
Ciproﬂoxacin. Removal in Full-Scale WWTPs. The fate of
CIP was investigated in CAS WWTPs,104,105,121 where the
elimination almost entirely occurred via sorption onto activated
sludge. In Figure S6a, ASM-X prediction curves for ηLI and
ηTOT were compared to measured removal eﬃciencies only for
parent CIP.104,105,121 Scenario simulations with ASM-X were
run assuming reduced inﬂuent loading (1/30th of original
loading32). Sorption equilibria in activated sludge were
simulated using the Freundlich isotherm equation (eq 6)
=C K C X/nSL f LI SS (6)
where XSS (gTSS L
−1) denotes the TSS concentration of
activated sludge and experimental values for the Freundlich
coeﬃcients Kf (10.6−10.7 μg1−n Ln g−1) and n (0.62−0.73)
under anoxic and aerobic conditions were used.124 Implemen-
tation of eq 6 in ASM-X rate equations is presented in
Table S2. Measured CIP removal eﬃciencies were in good
agreement with ASM-X predictions for ηTOT, indicating limited
retransformation and/or negligible concentrations of the
retransformable fraction (CCJ) in the WWTPs investigated.
Experimental and modeling studies13,59,104,105,121,229,230
showed the presence of relevant amounts of CIP sorbed onto
inﬂuent and eﬄuent solids. To further assess ASM-X predic-
tions when accounting for sorbed fractions, further scenario
simulations were run, assuming (i) negligible retransformable
fraction in the inﬂuent (CCJ,in = 0); (ii) sorbed CIP concen-
trations in secondary inﬂuent solids based on measured inﬂuent
TSS and CIP concentrations32 and Kd = 2 L gTSS
−1 for
primary sludge.105,121 On the basis of ASM-X predictions,
we calculated a removal eﬃciency (ηTOT,X) that accounts for
inﬂuent and eﬄuent loads of CIP sorbed onto solids (eq 7):
η = + − −
+
M M M M
M M
( )
/( )
TOT,X LI,in SL,in LI,eff SL,eff
LI,in SL,in (7)
where MSL,in and MSL,eff denote the mass loads of sorbed CIP
onto secondary inﬂuent and secondary eﬄuent solids,
respectively, and MLI,in and MLI,eff the mass loads of parent
CIP in secondary inﬂuent and eﬄuent, respectively. Similarly,
reported CIP concentrations in sorbed phase were used to
calculate measured ηTOT,X from full-scale investigations.
104,105,121
Predicted ηLI and ηTOT,X were in good agreement with measured
CIP removal eﬃciencies (Figure S6b−c). The deviation
between ηLI and ηTOT,X is shown to be rather small for ASM-X
predictions (0%−2%) and some of the full-scale measurements
(4%−5%105,121), whereas signiﬁcant deviation (35%) was also
reported.104 Although small compared to SMX, the variability
of measured ηLI and ηTOT,X for CIP may be attributed to
uncertainties intrinsic to analytical methods, in particular to the
extraction and quantiﬁcation in solid matrices.231
Zero-Catchment Scenario. CIP elimination was also
investigated in MBR treating hospital sewage.96 Measured
removal eﬃciencies, only referring to CIP in the aqueous
phase, were compared to ASM-X predictions for ηLI and ηTOT
(Figure S7a). Scenario simulations were performed assuming
4-fold increased inﬂuent loading using a Freundlich-based
sorption model (see above). Measured ηLI (29%−72%) were
close to ηTOT predictions, being signiﬁcantly higher than
predicted ηLI (lower than −150%). In analogy with ﬁndings for
full-scale WWTPs (Figure S6a), our results suggest insigniﬁcant
retransformation or alternatively the presence of negligible
retransformable CIP fraction. CIP removal prediction was
consequently assessed via new scenario simulations with
ASM-X, considering the retransformable fraction in secondary
inﬂuent negligible (CCJ,in = 0) and the presence of sorbed CIP
concentration in secondary inﬂuent solids (Kd = 2 L gTSS
−1).
New ηLI (and ηTOT,X, accounting for sorbed fractions in inﬂuent
and eﬄuent) predictions were obtained, in agreement with
measured ηLI (Figure S7b). We note that removal eﬃciencies
measured in the hospital MBR (Figure S7) were on average
lower than in full-scale WWTPs (Figure S6). CIP concentration
in sorbed phase was not measured, preventing a complete mass
balance. Nevertheless, reduced removal eﬃciency may be
attributed to less eﬃcient sorption (resulting from competition
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for or progressive saturation of sorption sites by pharmaceut-
icals at μg L−1 levels) or to the presence of conjugates (sulfo-
CIP) in inﬂuent. CIP elimination was also investigated in a full-
scale WWTP (primary clariﬁcation + MBR) treating hospital
eﬄuent.232,233 The investigation highlighted (a) the relevance
of sorption as removal mechanism and (b) an ∼10% deviation
between theoretical excreted CIP loads and inﬂuent loads to
WWTP, possibly corresponding to the amounts of CIP
excreted in faeces and/or in conjugated form (sulfo-CIP)
(Figure S4 and Table S1).
Tetracycline. Removal in Full-Scale WWTPs. Elimination
of TCY during biological wastewater treatment occurs via
sorption onto solid matrices (e.g., sludge), with limited
contribution from biotransformation.32,122,123 As previously
described for CIP, TCY exhibits signiﬁcant aﬃnity to solids
despite its low hydrophobicity (log D = −1.25 at pH 7; ACD/
Laboratories LogD). To our knowledge, no study documenting
TCY elimination during secondary wastewater treatment
satisﬁed the criteria set in this study for preliminary data
screening, e.g. the use of adequate sampling protocols. The
relevance of residual TCY in WWTP eﬄuents for environ-
mental risk assessment was thus discussed based only on
simulation results (see following paragraph). Evidence from
batch studies32,122,123 suggests signiﬁcant TCY removal from
the aqueous phase, as conﬁrmed by full-scale measurements32
(ηLI = 77% ± 8%). Similarly to CIP, variability in removal
eﬃciency determinations for TCY may be expected due to
uncertainties associated with analytical methods, including, for
example, the quantiﬁcation of TCY in solids and of matrix
eﬀects in inﬂuent and eﬄuent wastewater.231,234
Implications for Environmental Risk Assessment. Environ-
mental risk assessment (ERA) methodologies are used to
characterize the potential risk for ecological receptors from the
exposure to toxic chemicals released in the environment. ERAs
rely on the prediction of environmental concentrations (PECs)
at regional or local catchment level using a range of modeling
tools235 and on their comparison to PNECs derived from
ecotoxicological experiments. Guidelines for ERAs of pharma-
ceuticals have been proposed by the European Medicines
Agency (EMA) with integration from the REACH (Registra-
tion, Evaluation, Authorisation, and Restriction of Chemicals)
framework regulation.236 Emissions from WWTPs to receiving
water bodies are recognized as one of the major sources of
ecological exposure to pharmaceuticals.
A number of recommendations for the improvement of these
guidelines have been recently proposed.237−241 Importantly,
ERAs are typically conducted by simulating nondynamic release
of pharmaceuticals from WWTPs, thus estimating steady-state
PECs. This appears to be a rather simpliﬁed approach when
considering (a) signiﬁcant intraday variations in eﬄuent
loads and concentrations of antibiotics;183,242 (ii) diﬀerences
in antibiotic consumption rates over the year.225 In addition,
the release of retransformable pharmaceutical fractions may
represent an additional source of risk, due to the potential
formation of parent pharmaceuticals in freshwater. Inclusion of
retransformable metabolites in ERA had been previously
recommended for estrogens.50,243
Considering these shortcomings, we present here an example
of ERA where dynamics in PECs and the contribution of
the retransformable fraction are accounted for when assessing
environmental risk in surface water. Speciﬁcally, we present
(Figure 4) the results of a preliminary ERA on the release of
TCY to receiving surface water from Bekkelaget WWTP
eﬄuent. Quasi-MECs, PECLI and PECTOT were calculated
based on three-day monitoring and modeling predictions32 and
compared to PNEC (acute toxicity data1). Two major evidence
sets are highlighted: (i) the signiﬁcant variations of quasi-MEC
and PECLI, temporarily exceeding the PNEC threshold in the
three-day time interval; (ii) the potential contribution of the
retransformable fraction to PECTOT and thus to the overall risk
associated with TCY. We note that our evaluation as to point
(ii) should be considered as speculative, since TCY retrans-
formation could not be addressed in this generalization study
by comparing ASM-X predictions to international full-scale mea-
surements. Furthermore, simulation results should be regarded as
preliminary since a ﬁxed dilution factor was assumed and more
complex hydrodynamic phenomena (downstream transport,
dispersion) were not considered. Nevertheless, considering
dynamics in WWTP eﬄuents and monitoring through multiple
days may be relevant for improvement of risk assessment
protocols, especially for acute toxicity eﬀects and in freshwater
streams having signiﬁcant contribution from WWTP eﬄu-
ents.237 In addition, the presence of potentially retransformable
fractions of pharmaceuticals can amplify the ecological risk, and
this hypothesis requires further investigation.
■ OUTLOOK AND IMPLICATIONS FOR FATE
ASSESSMENT IN WWTPS
In this Critical Review, we reviewed existing literature on the
fate of three widely consumed antibiotics (SMX, CIP, and
TCY) in biological WWTPs. Factors inﬂuencing their
Figure 4. Dynamic risk assessment of TCY in surface water
considering only parent (CLI) and parent + retransformable fractions
(CTOT = CLI + CCJ) released from WWTP. PECLI (green solid line)
and PECTOT (black dashed line) were calculated from ASM-X
predictions for eﬄuent TCY (dilution factor = 10216). PNEC of parent
TCY was obtained from acute toxicity data.1,221 Quasi-MECs (circles)
were estimated from measured parent TCY concentrations in
Bekkelaget WWTP eﬄuent.32 The evaluated time interval (3 d) refers
to the full-scale monitoring of Bekkelaget WWTP, used also for ASM-X
validation.32
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elimination were assessed using the Activated Sludge Modeling
framework for Xenobiotics (ASM-X) and measured removal
eﬃciency data obtained in pilot- and full-scale WWTPs.
First, we showed that retransformation, as a result of
metabolite deconjugation, can signiﬁcantly impair the elimi-
nation of SMX in full-scale WWTPs. The extent of retrans-
formation in diﬀerent WWTPs was adequately predicted by
ASM-X and likely explains the observed variability in SMX
removal eﬃciencies. The combined quantiﬁcation of parent and
conjugated pharmaceuticals is thus required to close mass
balances in WWTPs, as deconjugation is a relevant process to a
number of pharmaceuticals (among others, carbamazepine,
diclofenac, and sulfonamide antibiotics). Furthermore, we
could determine whether retransformation is expected to
prevail during secondary treatment or in upstream sewer
systems. Among the responsible factors we identiﬁed the
catchment size, with extensive retransformation in sewer
systems of larger catchments. Diﬀerent excretion patterns of
SMX and its conjugated metabolites in hospitals and house-
holds were considered to explain observations in a WWTP
treating hospital sewage, with negligible upstream in-sewer
transport. This further indicates that substantial amounts of
antibiotics administered in hospitals are not excreted to hospital
sewage (but, e.g., in households), as conﬁrmed in a recent
nationwide study.226
The generalization of ASM-X predictions with full-scale
measurements further suggested a step enhancement of SMX
biotransformation kinetics undergo at SRT ≥ 16 d, thereby
resulting in improved SMX elimination in full-scale WWTPs
and in agreement with previous evidence for diclofenac.33
Currently available experimental evidence is not suﬃcient to
conﬁrm this ﬁnding, and further research may be required for
the quantiﬁcation of transformation kinetics in treatment
systems (MBRs, bioﬁlms) operating at extended SRT.244
Retransformation processes were shown to be not signiﬁcant
for CIP fate in biological treatment systems, even though
limited empirical evidence in full-scale WWTPs was available to
conﬁrm this conclusion. ASM-X predictions allowed estimating
the signiﬁcance of sorbed fractions in inﬂuent and eﬄuent
solids when determining CIP removal eﬃciency.
Using TCY as an example, we showed that dynamics in
eﬄuent loading and the presence of residual retransformable
fraction can have signiﬁcant implications on the assessment of
the environmental risk in surface water. Conclusions as to the
signiﬁcance of the retransformable fraction have not yet been cor-
roborated by empirical evidence, and further research (combining
full-scale measurements and model predictions) is required to
address this question for this and other pharmaceuticals.
The presented methodology is relevant to the prediction of:
(i) WWTP elimination of other pharmaceuticals presenting
similar characteristics to the ones assessed in this study (e.g.,
sulfonamides, consistently present in wastewater in acetylated
form); and (ii) maximum removal eﬃciencies of pharmaceuticals
in full-scale WWTPs, thus complementing laboratory-scale
experimental studies.245 Overall, our ﬁndings suggest the adoption
of an integrated approach for the evaluation of antibiotic removal
in full-scale WWTPs, where excretion and in-sewer fate processes
are considered within the boundaries of the systems investigated.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.est.6b01899.
Details on the use of antibiotics selected in this study
(S1) and on their metabolism and excretion in humans
(S2), description of the activated sludge modeling
framework for xenobiotics (ASM-X) (S3), overview of
existing literature on the inﬂuence of SRT on the
removal of pharmaceuticals in WWTPs (S4), description
and examples of the model generalization methodology
through the graphical comparison of measured and
predicted removal eﬃciency (S5), metabolic pathways
for sulfamethoxazole, ciproﬂoxacin, and tetracycline
(Figures S1−S3), excreted fractions of parent and
metabolites in selected human pharmacokinetic studies
(Figure S4), examples of operating plots used for ASM-X
generalization (Figure S5), operating plots for cipro-
ﬂoxacin considering measured removal eﬃciency data in
full-scale WWTPs and in zero-catchment scenario
(Figures S6 and S7), summary of metabolism and
excretion studies on sulfamethoxazole, ciproﬂoxacin, and
tetracycline (Table S1), Gujer matrix of ASM-X (Table
S2), summary of scenario simulations using ASM-X
(Table S3), literature values of biotransformation and
retransformation rate constants for sulfamethoxazole
(Table S4), summary of literature studies reporting
removal eﬃciency data for sulfamethoxazole and
ciproﬂoxacin in municipal and hospital WWTPs
(Tables S5 and S6), and design capacity and residence
time in upstream sewer for selected WWTPs/catchments
(Table S7) (PDF)
■ AUTHOR INFORMATION
Corresponding Authors
*Telephone: +45 5269 0014. E-mail: fabp@env.dtu.dk.
*Telephone: +45 4525 1694. E-mail: beep@env.dtu.dk.
Author Contributions
The authors declare no competing ﬁnancial interest. All authors
have given approval to the ﬁnal version of the manuscript.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
F.P. gratefully acknowledges ﬁnancial support from the
Technical University of Denmark, Department of Environ-
mental Engineering for a PhD research fellowship. The authors
thank Prof. Barth. F. Smets for fruitful discussion on the
manuscript. The authors are also grateful to Dr. Lubomira
Kovalova, Xin Yang, and Dr. Magnus Christensson for
providing details on their respective studies that were highly
beneﬁcial for the discussion presented in this Critical Review.
■ ABBREVIATIONS
ADBI celestolide
AHTN tonalide
ASM-X activated sludge model framework for xenobiotics
BE benzoyl-ecgonine
CAS conventional activated sludge
CBZ carbamazepine
CIP ciproﬂoxacin
CIT citalopram
COC cocaine
CYP cytochrome P
DCF diclofenac
DF dilution factor
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DZP diazepam
EE2 17α-ethinyl estradiol
EMA European Medicines Agency
EME ecgonine-methyl-ester
ERA environmental risk assessment
ERY erythromycin
FBR ﬁxed bed bioﬁlm reactor
FLX ﬂuoxetine
Glu glucuronide
HHCB galaxolide
HRT hydraulic retention time
HYBAS hybrid bioﬁlm activated sludge
IBP ibuprofen
MBBR moving bed bioﬁlm reactor
MBR membrane bioreactors
MEC measured environmental concentration
NPH nonylphenol
NPX naproxen
PE population equivalent
PEC predicted environmental concentration
PNEC predicted no-eﬀect concentration
REACH Registration, Evaluation, Authorisation, and Restric-
tion of Chemicals
ROX roxythromycin
RQ risk quotient
SAL salicylic acid
SMX sulfamethoxazole
SRT solid retention time
TCY tetracycline
TMP trimethoprim
WWTP wastewater treatment plant
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(46) Gurke, R.; Rößler, M.; Marx, C.; Diamond, S.; Schubert, S.;
Oertel, R.; Fauler, J. Occurrence and removal of frequently prescribed
pharmaceuticals and corresponding metabolites in wastewater of a
sewage treatment plant. Sci. Total Environ. 2015, 532, 762−770.
(47) Lee, H. J.; Lee, E.; Yoon, S. H.; Chang, H. R.; Kim, K.; Kwon, J.
H. Enzymatic and microbial transformation assays for the evaluation of
the environmental fate of diclofenac and its metabolites. Chemosphere
2012, 87 (8), 969−974.
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S.; Barcelo,́ D. Simultaneous determination of diclofenac, its human
metabolites and microbial nitration/nitrosation transformation prod-
ucts in wastewaters by liquid chromatography/quadrupole-linear ion
trap mass spectrometry. J. Chromatogr. A 2014, 1347, 63−71.
(94) Nödler, K.; Licha, T.; Barbieri, M.; Peŕez, S. Evidence for the
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(169) Kovaŕova-́Kovar, K.; Egli, T. Growth kinetics of suspended
microbial cells: From single-substrate-controlled growth to mixed-
substrate kinetics. Microbiol. Mol. Biol. Rev. 1998, 62 (3), 646−666.
(170) Egli, T. How to live at very low substrate concentration. Water
Res. 2010, 44 (17), 4826−4837.
(171) Ihssen, J.; Egli, T. Global physiological analysis of carbon- and
energy-limited growing Escherichia coli confirms a high degree of
catabolic flexibility and preparedness for mixed substrate utilization.
Environ. Microbiol. 2005, 7 (10), 1568−1581.
(172) Tan, D. T.; Arnold, W. A.; Novak, P. J. Impact of organic
carbon on the biodegradation of estrone in mixed culture systems.
Environ. Sci. Technol. 2013, 47 (21), 12359−12365.
(173) Helbling, D. E.; Johnson, D. R.; Honti, M.; Fenner, K.
Micropollutant biotransformation kinetics associate with WWTP
process parameters and microbial community characteristics. Environ.
Sci. Technol. 2012, 46 (19), 10579−10588.
(174) Smook, T. M.; Zho, H.; Zytner, R. G. Removal of ibuprofen
from wastewater: Comparing biodegradation in conventional,
membrane bioreactor, and biological nutrient removal treatment
systems. Water Sci. Technol. 2008, 57 (1), 1−8.
(175) Abegglen, C.; Joss, A.; McArdell, C. S.; Fink, G.; Schlüsener,
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